Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Compare after-tax performance between ETFs and mutual funds to understand tax efficiency and potential savings for your portfolio.
26,741 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Palantir stock popped today as investors weighed government contracts, AI adoption, and improving commercial momentum...
Blink Charging's Q1 2026 earnings set the tone for the year. This article breaks down what to watch, how to read the ...
Oil markets are heating up as supply constraints tighten. Here are three solid stock ideas to consider before prices ...
As SpaceX prepares to enter the public markets, investors face a mix of hype and risk. This guide unpacks what histor...
A stock surged 125% in 2026, turning heads across the market. This deep-dive breaks down the drivers of the move, how...
As mortgage rates shift and originations evolve, loandepot (LDI) 2025 earnings will hinge on rate flow, loan mix, and...
Rivian has faced a choppy 2026 after huge 2025 gains. This piece explains why april could turning point for Rivian in...
AST SpaceMobile has surged, leaving investors asking whether spacemobile buy, sell, hold makes sense now. This articl...
Lumentum’s March 23 S&P 500 inclusion has sparked renewed buying and a broader market debate about how far the rally ...
Investors eye Xcel Brands (XELB) 2026 as it reports Q1 results. This guide explains what to look for in the transcrip...
Target rolls out a broad turnaround, including redesigned carts and a baby concierge service, but investors question ...